Stocks
Incyte’s Monjuvi Lifts Lymphoma Survival 25% in Late-Stage Trial
Incyte's immunotherapy Monjuvi, developed with Xencor, demonstrated a 25% improvement in cancer-free survival in a late-stage trial for a common lymphoma type,...
#biotechnology 19 articles
Stocks
NervGen Pharma Prices $60 Million Public Offering
NervGen Pharma Corp. has priced a public offering of common shares and warrants, raising $60 million to advance its neuroreparative therapeutics.
Stocks
Ars Pharmaceuticals Expands $199 Access Program, Awaits CVS Caremark Decision
Ars Pharmaceuticals is expanding its $199 neffy retail access program while awaiting a crucial decision from CVS Caremark, aiming to boost affordability...
Stocks
LENZ Therapeutics Reports Q1 2026 Performance, Targets 15,000 HCPs
LENZ Therapeutics delivered Q1 2026 results consistent with expectations, achieving $1.9 million in net revenue and approximately 25,000 prescriptions. The company also...
Stocks
Vaxart Sets Early 2027 Efficacy Readout, Q2 Sentinel Data Release Imminent
Vaxart (VXRT) anticipates a primary efficacy readout for its oral vaccine platform in early 2027, with a Q2 sentinel data release expected...
Stocks
Recursion Projects 2028 Runway, Holds 2026 Expenses Below $390M
Recursion Pharmaceuticals projects its operational runway into early 2028 while committing to keep 2026 cash operating expenses under $390 million, driven by...
Stocks
Quantum BioPharma Taps Senergy, King Tide for Investor Outreach
Quantum BioPharma Ltd. has engaged Senergy Communications Capital Inc. and King Tide Media LLC for a one-month contract to bolster investor awareness...
Markets
Eli Lilly’s Diversification Offers Stronger Investment Case
Beyond its weight-loss drug success, Eli Lilly's robust pipeline across oncology, immunology, and neuroscience presents a compelling investment thesis.
Markets
Sartorius Stedim Biotech Posts Q1 Profit Growth, Reaffirms FY26 Outlook
Sartorius Stedim Biotech reported a rise in Q1 profit and revenue, driven by its consumables business, and confirmed its fiscal 2026 financial...